AR040048A1 - Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 - Google Patents
Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6Info
- Publication number
- AR040048A1 AR040048A1 ARP030101812A ARP030101812A AR040048A1 AR 040048 A1 AR040048 A1 AR 040048A1 AR P030101812 A ARP030101812 A AR P030101812A AR P030101812 A ARP030101812 A AR P030101812A AR 040048 A1 AR040048 A1 AR 040048A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- cycloalkyl
- aryl
- independently
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en la cual W es N o CR2; R es H, halógeno, CN, OCO2R7, CO2R8, CONR9R10, SOpR11, NR12R13, OR14, COR15 o un alquilo de C1-6, un alquenilo de C2-6, un alquinilo de C2-6, un cicloalquilo de C3-7, un grupo cicloheteroalquilo, arilo o heteroarilo, cada uno sustituido opcionalmente; R1 es un grupo alquilo de C1-6, cicloalquilo de C3-7, arilo o heteroarilo opcionalmente sustituidos o un sistema de anillos opcionalmente sustituido de 8 a 13 miembros bicíclico o tricíclico que tiene un átomo de N en la cabeza de puente y que contiene en forma opcional 1, 2 o 3 heteroátomos adicionales seleccionados de N, O o S; R2 es H, halógeno, o un grupo alquilo de C1-6, alcoxi de C1-6, cicloalquilo de C3-7, arilo o heteroarilo, cada uno opcionalmente sustituido; R3 y R4 son cada uno en forma independiente H, o un grupo alquilo de C1-6 opcionalmente sustituido; R5 y R6 son cada uno en forma independiente H o un grupo alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-7, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido o R5 y R6 se pueden tomar junto con el átomo al cual están unidos para formar un anillo opcionalmente sustituido de 5 a 8 miembros que contiene en forma opcional un heteroátomo adicional elegido de O, NR16 o SOx; m es 0 o un entero de valor 1, 2 o 3; n es un entero de valor 2, 3, 4 o 5; p y x son cada uno en forma independiente 0 o un entero de valor 1 o 2; R7, R8, R11, R15 y R16 son cada uno en forma independiente H o un grupo alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R9 y R10 son cada uno en forma independiente H o un grupo alquilo de C1-6 o cicloalquilo de C3-7, cada uno opcionalmente sustituido o R9 y R10 se pueden tomar juntos con el átomo al cual están unidos para formar un anillo de 5 a 7 miembros que contiene en forma opcional otro heteroátomo elegido de O, NR18 o S; R12 y R13 son cada uno en forma independiente H o un grupo alquilo de C1-4 opcionalmente sustituido o R12 y R13 se pueden tomar juntos con el átomo al cual están unidos para formar un anillo de 5 a 7 miembros que contiene en forma opcional otro heteroátomo elegido de O, NR17 o SOq; R14 es un grupo alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-7, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; q es 0 o un entero de valor 1 o 2; y R17 y R18 so cada uno en forma independiente H o un grupo alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-7, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido, o un estereoisómero del mismo o una sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38569502P | 2002-06-04 | 2002-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR040048A1 true AR040048A1 (es) | 2005-03-09 |
Family
ID=29712202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030101812A AR040048A1 (es) | 2002-06-04 | 2003-05-23 | Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 |
Country Status (21)
Country | Link |
---|---|
US (1) | US6727246B2 (es) |
EP (1) | EP1509501B1 (es) |
JP (1) | JP2005536473A (es) |
CN (1) | CN1656069A (es) |
AR (1) | AR040048A1 (es) |
AT (1) | ATE348806T1 (es) |
AU (1) | AU2003237355A1 (es) |
BR (1) | BR0311436A (es) |
CA (1) | CA2485871A1 (es) |
CR (1) | CR7566A (es) |
DE (1) | DE60310552T2 (es) |
DK (1) | DK1509501T3 (es) |
EC (1) | ECSP045473A (es) |
ES (1) | ES2279125T3 (es) |
MX (1) | MXPA04011315A (es) |
NO (1) | NO20044764L (es) |
NZ (1) | NZ536921A (es) |
RU (1) | RU2004139099A (es) |
TW (1) | TW200400177A (es) |
WO (1) | WO2003101962A1 (es) |
ZA (1) | ZA200500021B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL370342A1 (en) * | 2001-09-27 | 2005-05-16 | F.Hoffmann-La Roche Ag | Indole derivatives as cox ii inhibitors |
KR20040085179A (ko) * | 2002-02-13 | 2004-10-07 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 통합된 반도체 광학 디바이스, 이러한 디바이스를제조하는 방법 및 장치 |
TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2004074243A2 (en) * | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
EP1647549A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
EP1899340A4 (en) * | 2005-06-28 | 2009-09-16 | Merck & Co Inc | NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS |
CA2612592A1 (en) * | 2005-06-28 | 2007-01-04 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
AU2006261954A1 (en) * | 2005-06-28 | 2007-01-04 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
RU2429231C2 (ru) * | 2005-08-15 | 2011-09-20 | Вайет | Производные замещенного-3-сульфонилиндазола в качестве лигандов 5-гидрокситриптамина-6 |
MX2008002158A (es) * | 2005-08-15 | 2008-04-19 | Wyeth Corp | Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6. |
WO2007053353A2 (en) * | 2005-10-28 | 2007-05-10 | Wyeth | Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
WO2007117413A1 (en) * | 2006-04-05 | 2007-10-18 | Wyeth | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
AU2008256859A1 (en) * | 2007-05-24 | 2008-12-04 | Memory Pharmaceuticals Corporation | 4' substituted compounds having 5-HT6 receptor affinity |
US20090012308A1 (en) * | 2007-06-13 | 2009-01-08 | Wyeth | Process for the manufacture of benzylsulfonylarenes |
US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
KR20150032329A (ko) * | 2012-07-10 | 2015-03-25 | 에프. 호프만-라 로슈 아게 | 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 인다졸 |
WO2018064094A1 (en) | 2016-09-28 | 2018-04-05 | Bristol-Myers Squibb Company | Enantioselective synthesis of pyrroloindole compounds |
WO2018165501A1 (en) * | 2017-03-10 | 2018-09-13 | Lycera Corporation | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE |
CN111269165A (zh) * | 2018-12-05 | 2020-06-12 | 中国科学院大连化学物理研究所 | 一种3-芳基磺酰基吲哚衍生物的合成方法 |
SG11202109111VA (en) | 2019-02-27 | 2021-09-29 | Univ California | Azepino-indoles and other heterocycles for treating brain disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4654360A (en) | 1984-06-01 | 1987-03-31 | Syntex (U.S.A.) Inc. | 1,2,3-trisubstituted indoles for treatment of inflammation |
FR2642755B1 (es) | 1989-02-07 | 1993-11-05 | Sanofi | |
US5132319A (en) | 1991-03-28 | 1992-07-21 | Merck Frosst Canada, Inc. | 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis |
US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
UA59443C2 (uk) | 1998-04-28 | 2003-09-15 | Арцнайміттельверк Дрезден Гмбх | Гідроксііндол, спосіб його одержання, лікарська форма на його основі та спосіб її одержання |
GB9819032D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds IV |
GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
EP1276720B1 (de) | 2000-04-28 | 2006-12-20 | Baxter Healthcare S.A. | 2-acyl-indolderivate und deren verwendung als antitumormittel |
JP4187642B2 (ja) * | 2001-06-07 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を有する新規インドール誘導体 |
-
2003
- 2003-05-19 TW TW092113450A patent/TW200400177A/zh unknown
- 2003-05-23 AR ARP030101812A patent/AR040048A1/es unknown
- 2003-06-03 CN CNA038124998A patent/CN1656069A/zh active Pending
- 2003-06-03 WO PCT/US2003/017472 patent/WO2003101962A1/en active IP Right Grant
- 2003-06-03 MX MXPA04011315A patent/MXPA04011315A/es active IP Right Grant
- 2003-06-03 AU AU2003237355A patent/AU2003237355A1/en not_active Withdrawn
- 2003-06-03 DK DK03736818T patent/DK1509501T3/da active
- 2003-06-03 JP JP2004509655A patent/JP2005536473A/ja active Pending
- 2003-06-03 CA CA002485871A patent/CA2485871A1/en not_active Withdrawn
- 2003-06-03 BR BR0311436-8A patent/BR0311436A/pt not_active IP Right Cessation
- 2003-06-03 US US10/453,009 patent/US6727246B2/en not_active Expired - Fee Related
- 2003-06-03 ES ES03736818T patent/ES2279125T3/es not_active Expired - Lifetime
- 2003-06-03 AT AT03736818T patent/ATE348806T1/de not_active IP Right Cessation
- 2003-06-03 RU RU2004139099/04A patent/RU2004139099A/ru not_active Application Discontinuation
- 2003-06-03 EP EP03736818A patent/EP1509501B1/en not_active Expired - Lifetime
- 2003-06-03 DE DE60310552T patent/DE60310552T2/de not_active Expired - Lifetime
- 2003-06-03 NZ NZ536921A patent/NZ536921A/en unknown
-
2004
- 2004-11-03 NO NO20044764A patent/NO20044764L/no not_active Application Discontinuation
- 2004-11-04 CR CR7566A patent/CR7566A/es unknown
- 2004-12-02 EC EC2004005473A patent/ECSP045473A/es unknown
-
2005
- 2005-01-03 ZA ZA200500021A patent/ZA200500021B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1509501B1 (en) | 2006-12-20 |
CA2485871A1 (en) | 2003-12-11 |
NZ536921A (en) | 2006-06-30 |
CN1656069A (zh) | 2005-08-17 |
ATE348806T1 (de) | 2007-01-15 |
AU2003237355A1 (en) | 2003-12-19 |
DE60310552D1 (de) | 2007-02-01 |
ECSP045473A (es) | 2005-01-28 |
NO20044764L (no) | 2005-01-03 |
RU2004139099A (ru) | 2005-06-10 |
ES2279125T3 (es) | 2007-08-16 |
WO2003101962A1 (en) | 2003-12-11 |
JP2005536473A (ja) | 2005-12-02 |
US20030232828A1 (en) | 2003-12-18 |
ZA200500021B (en) | 2006-06-28 |
MXPA04011315A (es) | 2005-02-14 |
CR7566A (es) | 2005-01-05 |
DE60310552T2 (de) | 2007-09-27 |
TW200400177A (en) | 2004-01-01 |
BR0311436A (pt) | 2005-03-22 |
US6727246B2 (en) | 2004-04-27 |
DK1509501T3 (da) | 2007-03-12 |
EP1509501A1 (en) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR040048A1 (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 | |
AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
AR043180A1 (es) | Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR037906A1 (es) | Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR064345A1 (es) | Derivados de 8-oxoadenina | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR043938A1 (es) | Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
AR069691A1 (es) | Derivados ciclopropilamina | |
AR055401A1 (es) | Derivados de benzotiazolona | |
ES2393824T3 (es) | Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
AR054090A1 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
AR075605A1 (es) | Derivados de imidazolilpirazina | |
AR070343A1 (es) | Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
AR061026A1 (es) | Compuesto glicitol c-fenilo y preparacion farmaceutica | |
AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |